Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 447 of 641 · 7,691 filings

  • VerifyMe (VRME) FY2024 10-K risk factors
    43 risks

    The company relies heavily on a single strategic shipping partner for its PeriShip Global logistics segment. Profitability is threatened by a history of operating losses and potential goodwill impairment. Future growth depends on commercializing technologies and executing acquisitions within competitive markets.

    Filed Mar 12, 2025
  • Vitesse Energy (VTS) FY2024 10-K risk factors
    49 risks

    Vitesse Energy faces concentrated risks from commodity price volatility, dependence on third-party operators, and geographical concentration in the Williston Basin. Borrowing base redeterminations and restrictive credit facility covenants directly constrain liquidity and dividend capacity. Stringent environmental regulations and federal land restrictions threaten exploration and development activities.

    Filed Mar 12, 2025
  • Westrock Coffee (WEST) FY2024 10-K risk factors
    31 risks

    Production and distribution are concentrated in North Carolina, Arkansas, Malaysia, and Johor Bahru facilities. The company incurred net losses of $80.3 million in 2024. Total debt stands at $447.7 million, with $371.1 million carrying variable interest rates.

    Filed Mar 12, 2025
  • Solitario Resources (XPL) FY2024 10-K risk factors
    21 risks

    Solitario Resources faces high exposure to gold and zinc prices, foreign asset sovereignty in Peru, and funding constraints for mineral exploration. The company has a history of losses, reporting net income in only three of 31 years of operations.

    Filed Mar 12, 2025
  • Zevra Therapeutics (ZVRA) FY2024 10-K risk factors
    115 risks

    Zevra relies heavily on the commercial success of its rare disease products MIPLYFFA and OLPRUVA. Market adoption depends on physician acceptance, third-party payor reimbursement, and competing therapies like AQNEURSA. Strict regulatory compliance, including FDA post-approval requirements and controlled substance laws, governs product manufacturing and distribution.

    Filed Mar 12, 2025
  • Redwire (RDW) FY2024 10-K risk factors
    53 risks

    Redwire depends heavily on government and other concentrated customers, cancellable backlog, and fixed-price contracts.

    Filed Mar 11, 2025
  • Workday (WDAY) FY2025 10-K risk factors
    40 risks

    AI-powered enterprise cloud applications create regulatory, reputational, litigation, and product-development risks.

    Filed Mar 11, 2025
  • Achieve Life Sciences (ACHV) FY2024 10-K risk factors
    76 risks

    Achieve Life Sciences relies entirely on a single clinical product candidate, cytisinicline, sourced from a single Bulgarian supplier, Sopharma AD. The company faces significant financial risks, including $10.0 million in debt as of December 31, 2024, and a complete lack of product revenue.

    Filed Mar 11, 2025
  • AES (AES) FY2024 10-K risk factors
    41 risks

    The company faces significant exposure to regulatory uncertainty in U.S. renewable energy incentives and import tariffs. Operations involve massive international reach, particularly in developing countries, alongside high commodity price volatility. The capital structure relies heavily on approximately $29 billion of consolidated debt and subsidiary cash flows.

    Filed Mar 11, 2025
  • AerSale (ASLE) FY2024 10-K risk factors
    41 risks

    AerSale faces key risks from supply chain disruptions, commercial aviation cyclicality, and aviation product value fluctuations. Operations depend heavily on skilled mechanics, leased MRO facilities, and specialized supplier components. Regulatory oversight by the FAA and compliance with international trade sanctions are critical.

    Filed Mar 11, 2025
  • BridgeBio Oncology Therapeutics (BBOT) FY2024 10-K risk factors
    65 risks

    This company is a special purpose acquisition company (SPAC) formed to complete an initial business combination, specifically the BBOT Business Combination. Risks are dominated by shareholder redemption mechanics, trust account protections, and potential target qualification issues. Operations and investments depend entirely on successfully acquiring a target business within the allotted completion window.

    Filed Mar 11, 2025
  • Mobile Infrastructure (BEEP) FY2024 10-K risk factors
    59 risks

    Mobile Infrastructure Corp relies heavily on parking facility demand and two key operators, Metropolis and LAZ, exposing the business to sector concentration and tenant risk. The company faces significant near-term debt obligations, including a $40.4 million revolving credit facility maturing in September 2025. Internal control weaknesses and net losses highlight ongoing financial reporting and profitability challenges.

    Filed Mar 11, 2025

Companies covered

4,011 companies

371 more under A